Ribociclib is named as an intervention in 38 current clinical trials in our USA, UK, China, India and Ireland registers. 20 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Novartis Pharmaceuticals (9). The most-studied condition is Breast Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
1 single-substance product containing Ribociclib on the HPRA medicines list.
No entry for Ribociclib in the EMA, FDA or German BfArM shortage lists we track.
| Condition (as registered) | Trials |
|---|---|
| Breast Cancer | 17 |
| Metastatic Breast Cancer | 7 |
| Early Breast Cancer | 2 |
| HR+/HER2- Breast Cancer | 2 |
| ER-Positive HER2-Negative Breast Cancer | 2 |
| Advanced Breast Cancer | 2 |
| Solid Tumor, Adult | 2 |
| HER2-negative Breast Cancer | 2 |
| Breast Neoplasms | 1 |
| Neoplasm Metastasis | 1 |
| Solid Tumors, Adult | 1 |
| Solid Tumors | 1 |
| Locally Advanced (Inoperable) or Metastatic Breast Cancer | 1 |
| ER+ HER2- Advanced Breast Cancer | 1 |
| High-grade Serous Ovarian Cancer (HGSOC) | 1 |
| Melanoma | 1 |
| Locally Advanced Breast Cancer | 1 |
| ER Positive Breast Cancer | 1 |
| Advanced HR+/HER2- Breast Cancer | 1 |
| Advanced CCNE1-amplified Solid Tumors | 1 |
| Extensive-stage Small Cell Lung Cancer | 1 |
| Advanced Solid Tumor | 1 |
| HR+, HER2-, Advanced Breast Cancer | 1 |
| CCNE1 Amplification | 1 |
| Advanced Cancer | 1 |
| Advanced Solid Tumors | 1 |
| PI3K Gene Mutation | 1 |
| PIK3CA Mutation | 1 |
| HER2 Mutation-Related Tumors | 1 |
| KRAS G12C Mutant Solid Tumors | 1 |
| Carcinoma, Non-Small Cell Lung | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Non-Small Cell Lung Cancer | 1 |
| Malignant Neoplasm of Breast | 1 |
| ER-positive Breast Cancer | 1 |
| Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer | 1 |
| Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer | 1 |
| Breast Cancer Stage I | 1 |
| Breast Cancer Stage II | 1 |
| Locally Advanced Breast Cancer (LABC) | 1 |
| Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies | 1 |
| Lead sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 9 |
| Hoffmann-La Roche | 5 |
| AstraZeneca | 5 |
| Pfizer | 3 |
| Eli Lilly and Company | 2 |
| Olema Pharmaceuticals, Inc. | 2 |
| Stemline Therapeutics, Inc. | 1 |
| BeOne Medicines | 1 |
| Incyte Corporation | 1 |
| Avenzo Therapeutics, Inc. | 1 |
| OnKure, Inc. | 1 |
| Relay Therapeutics, Inc. | 1 |
| TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 1 |
| Celcuity Inc | 1 |
| Forward Pharmaceuticals Co., Ltd. | 1 |
+ 3 more sponsors in the trial list above.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 34 | 17 |
| Clinical trials in UK | 16 | 8 |
| Clinical trials in China | 16 | 9 |
| Clinical trials in India | 6 | 2 |
| Clinical trials in Ireland | 4 | 2 |
A trial with sites in more than one country appears in each of those registers.
38 current trials in our USA, UK, China, India and Ireland registers name Ribociclib (also registered as RO7072612) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 20 of the 38 trials are recruiting: 17 with sites in USA, 8 with sites in UK, 9 with sites in China, 2 with sites in India and 2 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Novartis Pharmaceuticals (9), Hoffmann-La Roche (5), AstraZeneca (5) and Pfizer (3), among 18 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 1 single-substance product containing Ribociclib, for example Kisqali 200 mg film-coated tablets (Novartis Europharm Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Ribociclib has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ribociclib works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how Ribociclib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ribociclib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.